-+ 0.00%
-+ 0.00%
-+ 0.00%
Nicox says FDA accepts NCX 470 glaucoma NDA, sets April 2027 PDUFA date
Share
Listen to the news
Nicox says FDA accepts NCX 470 glaucoma NDA, sets April 2027 PDUFA date
  • Nicox reported the FDA accepted Kowa’s U.S. NDA filing for glaucoma drug candidate NCX 470.
  • Regulator set a PDUFA action date of April 30, 2027.
  • Approval would trigger a milestone payment to Nicox, with U.S. launch targeted for H2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270130PRIMZONEFULLFEED1001259509) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending